BeyondSpring (Nasdaq:BYSI) - Aandelenkoers, Nieuws & Analyse

BYSI Overzicht aandelen

BeyondSpring Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich samen met zijn dochterondernemingen op de ontwikkeling van kankertherapieën.

Over het bedrijf

BYSI fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Earnings have grown 15.4% per year over the past 5 years

Risicoanalyse

Negative shareholders equity

Does not have meaningful revenue ($2M)

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($90M)

BeyondSpring Inc. Concurrenten

Cidara Therapeutics

NasdaqCM:CDTX

US$92.1m

Protalix BioTherapeutics

NYSEAM:PLX

US$91.9m

CASI Pharmaceuticals

NasdaqCM:CASI

US$90.4m

Sorrento Therapeutics

OTCPK:SRNE.Q

US$60.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BeyondSpring
Historische aandelenkoersen
Huidige aandelenkoers	US$2.23
52 Week Hoogtepunt	US$4.00
52 Week Laag	US$0.78
Bèta	0.27
11 maand verandering	-5.91%
3 maanden verandering	23.20%
1 Jaar Verandering	129.21%
33 jaar verandering	-85.01%
5 jaar verandering	-81.97%
Verandering sinds IPO	-86.73%

Recent nieuws en updates

Recent updates

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

Rendement voor aandeelhouders

	BYSI	US Biotechs	US Markt
7D	1.4%	-0.7%	-1.6%
1Y	129.2%	19.8%	30.8%

Rendement versus industrie: BYSI exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: BYSI exceeded the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is BYSI's price volatile compared to industry and market?
BYSI volatility
BYSI Average Weekly Movement	7.5%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: BYSI has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: BYSI's weekly volatility has decreased from 16% to 7% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	36	Lan Huang	beyondspringpharma.com

BeyondSpring Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich samen met zijn dochterondernemingen op de ontwikkeling van kankertherapieën. De belangrijkste troef van het bedrijf is Plinabulin, een selectieve immunomodulerende microtubule-bindende stof die klinische Fase III-studies heeft voltooid voor de behandeling van niet-kleincellige longkanker (NSCLC); en als een middel tegen kanker, evenals voor de preventie van chemotherapie-geïnduceerde neutropenie. Het ontwikkelt ook Plinabuline in combinatie met docetaxel versus docetaxel alleen voor de behandeling van NSCLC en epidermale groeifactor receptor wild type.

BeyondSpring Inc. Samenvatting

Hoe verhouden de winst en inkomsten van BeyondSpring zich tot de beurswaarde?
BYSI fundamentele statistieken
Marktkapitalisatie	US$89.87m
Inkomsten(TTM)	-US$15.57m
Inkomsten(TTM)	US$1.88m

47.9x

P/S-verhouding

-5.8x

Koers/Winstverhouding

Is BYSI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BYSI resultatenrekening (TTM)
Inkomsten	US$1.88m
Kosten van inkomsten	US$0
Brutowinst	US$1.88m
Overige uitgaven	US$17.44m
Inkomsten	-US$15.57m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.39
Brutomarge	100.00%
Nettowinstmarge	-829.85%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde BYSI op de lange termijn?

Bekijk historische prestaties en vergelijking

BYSI Overzicht aandelen

Beloningen

Risicoanalyse

BeyondSpring Inc. Concurrenten

NasdaqCM:CDTX

US$92.1m

NYSEAM:PLX

US$91.9m

NasdaqCM:CASI

US$90.4m

OTCPK:SRNE.Q

US$60.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)

New minor risk - Shareholder dilution

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

Recent updates

BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)

New minor risk - Shareholder dilution

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

New major risk - Revenue and earnings growth

BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity

New minor risk - Financial data availability

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$2.30

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Price target decreased to US$6.10

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Consensus forecasts updated

Price target increased to US$13.67

BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022

BeyondSpring, Beyond Salvage

BeyondSpring Pharmaceuticals Announces Organizational Streamlining

Consensus revenue estimates fall by 90%

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition

Consensus forecasts updated

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

No longer forecast to breakeven

Circling Back On BeyondSpring

Price target decreased to US$58.60

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Price target increased to US$67.25

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Consensus forecasts updated

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value Index

Consensus forecasts updated

BeyondSpring EPS misses by $0.04

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

BeyondSpring EPS misses by $0.17

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Chief Scientific Officer has left the company

BeyondSpring Inc. Announces Management Changes

Price target lowered to US$36.00

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors